You searched for "Clinics"
Risk factors identified for glaucoma progression in paediatric glaucoma suspects
A retrospective case review was conducted of children (<18 years) identified as being glaucoma suspects using common clinical criteria or the Childhood Glaucoma Research Network definition. Exclusion criteria included penetrating ocular trauma, treated ocular hypertension / glaucoma and use of...Patient reported outcomes in adolescents with inherited retinal diseases
4 October 2023
| Ian Reekie
|
EYE - Vitreo-Retinal
|
PROM, Patient-reported outcomes, clinical trial, gene therapy, inherited retinal disease, pediatrics, retinal dystrophy
This was a two-centre validation study of two sets of patient reported outcome measures (PROMS) for adolescents (13-17- years-old) with inherited retinal diseases. The measures were the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Both...
Driving with retinitis pigmentosa
4 December 2023
| Ian Reekie
|
EYE - Vitreo-Retinal
|
Inherited retinal disease, driving standards, retinal dystrophy, retinal imaging, retinitis pigmentosa, visual field testing
The authors present a study of 228 consecutive patients with a clinical or genetic diagnosis of retinitis pigmentosa. Data was collected prospectively between January 2012 and October 2022 in Perth, Australia. The study aimed to determine the proportion of patients...
PRPF31-related retinitis pigmentosa and asymptomatic carriers
1 March 2024
| Ian Reekie
|
EYE - Vitreo-Retinal
|
FST, PRPF31, RP11, Retinitis pigmentosa, asymptomatic carriers, non-penetrance
The authors present a study of 21 patients with variants in the PRPF31 gene classified as pathogenic or likely pathogenic. These variants are caused by autosomal dominant retinitis pigmentosa (RP-11). Between January 2020 and November 2021 patients underwent tests of...
Pilot trial of Fluoxetine for post-stroke homonymous hemianopia
3 April 2024
| Lauren R Hepworth
|
EYE - Neuro-ophthalmology
The authors present a pilot randomised placebo controlled double blind trial assessing 20mg fluoxetine once daily for 90 days versus placebo in stroke survivors with isolated homonymous hemianopia. Exclusion criteria were extensive in terms of pre-existing ophthalmic or neurologic disease,...
Treatment of progressive keratoconus
This study aimed to analyse the clinical results of accelerated iontophoresis-assisted epithelium corneal cross-linking (i-ON CXL) to evaluate the risk factors for keratoconus progression after treatment, and the safety and efficacy of re-treatment using epithelium-off CXL protocol in paediatric patients....Clinical features of basic acquired nonaccommodative esotropia requiring surgery
Basic acquired nonaccommodative esotropia (BANAET) is a concomitant esotropia occurring after the age of six months without significant refractive error or accommodative element. Esotropia is similar for both near and distance and children have prior binocular single vision. The purpose...Being more consistent with screening for convergence insufficiency
This prospective cases series aimed to identify the average values and sensitivity of clinical measurements of convergence to aid diagnosis of convergence insufficiency (CI). Children and adults presenting over a two-year period with symptoms including diplopia when reading, headache with...Features of bacterial orbital cellulitis on MRI imaging
This multi-centre retrospective study from Australia and the UK examined the quantitative and qualitive parameters of magnetic resonance imaging (MRI) imaging in bacterial orbital cellulitis. Twenty MRI scans from 20 patients with pre-septal and orbital fat involvement (mean age: 40.8...Choroideremia in women
2 June 2025
| Ian Reekie
|
EYE - Vitreo-Retinal
The authors report a questionnaire-based study of female carriers of choroideremia, an X-linked inherited chorioretinal dystrophy. As an X-linked condition the full clinical features are predominantly seen in men but a proportion of women suffer some morbidity, likely due to...
Exciting opportunities for ophthalmic surgeons with the UK and Europe’s leading provider of cataract surgery, lens replacement surgery and laser eye surgery.
20 March 2023
|
Recruitment & Personnel
We have opportunities across the UK and Ireland for ophthalmic surgeons to treat private pay, PMI and NHS funded patients.
Darren Hargreaves joins Sense Medical as Clinical Solutions Director
26 July 2023
|
Recruitment & Personnel
Sense Medical Ltd welcomes the new appointment of Darren Hargreaves as Clinical Solutions Director.